Company intelligence / Profile preview

Quercegen Pharmaceuticals

Marlborough, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Quercegen’s lead program uses a proprietary, high-purity quercetin formulation for chronic obstructive pulmonary disease (COPD) now in Phase II trials, and a next-generation PDI inhibitor, Kinisoquin, in Phase III for cancer-associated thromboembolism; its plant-derived small molecules and formulations are supported by both preclinical and clinical studies showing disease-modifying and safety benefits[1][3][7].

Therapeutic areas: OncologyImmunologyCardiovascularPulmonologyHematology
Modalities: Small moleculeFlavonoid
Industry: Biotech

Drug pipeline

1 asset

Q-Mix

Unknown

Partnerships

National Institutes of Health (NIH)Temple UniversityNational Center for Complementary and Integrative Health (NCCIH)(academic: University of Michigan, others via clinical trial collaborations)

Beyond the preview

Go deeper on Quercegen Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quercegen Pharmaceuticals.

Explore the full profile